. 2021 Jun 26;1(2):100034. doi: 10.1016/j.xops.2021.100034

Table 1.

Characteristics of the Study Participants and Eyes

Participant No.	Age at Baseline (yrs)	Sex	Eye	Snellen Best-corrected Visual Acuity at Baseline	Age-Related Macular Degeneration Status	Number of Anti–VEGF Injections before Study Period	Time since Last Anti–VEGF Injection before Baseline (days)	Anti–VEGF drug used during study period
1	80	Male	Right	20/40	Neovascular	>10	18	Aflibercept
1	80	Male	Left	20/40	Intermediate	N/A	N/A	N/A
2	69	Female	Right	20/25	Neovascular	5	61	Aflibercept
2	69	Female	Left	20/40	Neovascular	8	46	Aflibercept
3	76	Female	Right	20/20	Neovascular	>10	6	N/A
3	76	Female	Left	20/133	Neovascular	>10	41	N/A
4	70	Female	Right	20/40	Intermediate	N/A	N/A	N/A
4	70	Female	Left	20/40	Neovascular	9	10	N/A
5	85	Male	Right	20/25	Neovascular	30	43	Ranibizumab
5	85	Male	Left	20/40	Neovascular	5	29	Ranibizumab

N/A = not applicable; VEGF = vascular endothelial growth factor.